Clinical Trial Update: Clinical Evaluation of Flortaucipir F 18 [Phase 2]

View source ↗

Summary

Phase 2 clinical evaluation of flortaucipir F18 completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Traumatic Brain Injury

Drugs mentioned

• Flortaucipir F18 (flortaucipir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease, Traumatic Brain Injury | Phase 2 | Status: COMPLETED | Results posted: 2020-09-10